EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER

Arshad M Khanani, Srinivas R Sadda, David Sarraf, Ramin Tadayoni, David T Wong, Anne-Sophie Kempf, Insaf Saffar, Kinfemichael Gedif, Andrew Chang

Ophthalmology Retina · 2025

DOI: 10.1016/j.oret.2024.07.012 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2025. Verfasst von Arshad M Khanani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sierra Eye Associates, Reno, Nevada; Reno School of Medicine, University of Nevada, Reno, Nevada. Electronic address: arshad.khanani@gmail.com. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Tomography, Optical Coherence, Intravitreal Injections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTomography, Optical CoherenceIntravitreal InjectionsRetinal Pigment EpitheliumAngiogenesis InhibitorsRetinal DetachmentVisual AcuityWet Macular DegenerationSubretinal FluidHumansDouble-Blind MethodProspective StudiesMaleFemaleAgedTreatment OutcomeAntibodies, Monoclonal, HumanizedFluorescein AngiographyFollow-Up StudiesDose-Response Relationship, DrugVascular Endothelial Growth Factor AFundus Oculi

Stichwörter der Autor:innen

AfliberceptBrolucizumabNeovascular age-related macular degenerationPigment epithelial detachmentsSub-retinal pigment epithelium

Substanzen

Receptors, Vascular Endothelial Growth FactorafliberceptRecombinant Fusion ProteinsbrolucizumabAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Sierra Eye Associates, Reno, Nevada; Reno School of Medicine, University of Nevada, Reno, Nevada. Electronic address: arshad.khanani@gmail.com.
  • Doheny Eye Institute, University of California, Los Angeles, Los Angeles, California.
  • Stein Eye Institute, University of California, Los Angeles, Los Angeles, California; Ophthalmology, Greater Los Angeles VA Healthcare Center, Los Angeles, California.
  • Department of Ophthalmology, Université Paris Cité, AP-HP, Lariboisière, Saint Louis and Fondation Adolphe de Rothschild Hospitals, Paris, France.
  • Department of Ophthalmology and Vision Sciences, Unity Health Toronto - St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Novartis Pharma AG, Basel, Switzerland.

Zitieren

APA

Khanani, A. M., Sadda, S. R., Sarraf, D., Tadayoni, R., Wong, D. T., Kempf, A. S., Saffar, I., Gedif, K., & Chang, A. (2025). Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2024.07.012

Vancouver

Khanani AM, Sadda SR, Sarraf D, Tadayoni R, Wong DT, Kempf AS, et al. Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER. Ophthalmology Retina. 2025. doi:10.1016/j.oret.2024.07.012

BibTeX
@article{Khanani2025,
  author = {Khanani, Arshad M and Sadda, Srinivas R and Sarraf, David and Tadayoni, Ramin and Wong, David T and Kempf, Anne-Sophie and Saffar, Insaf and Gedif, Kinfemichael and Chang, Andrew},
  title = {Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER},
  journal = {Ophthalmology Retina},
  year = {2025},
  doi = {10.1016/j.oret.2024.07.012}
}
Kostenlos starten →